Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
3(60%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_1
2
40%
Ph phase_2
3
60%

Phase Distribution

2

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
3(60.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

5

all time

Status Distribution
Active(3)
Completed(2)

Detailed Status

Active, not recruiting3
Completed2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
3
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (40.0%)
Phase 23 (60.0%)

Trials by Status

completed240%
active_not_recruiting360%

Recent Activity

3 active trials
Showing 5 of 5
active_not_recruitingphase_2

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)

NCT05269394
active_not_recruitingphase_2

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

NCT01760005
active_not_recruitingphase_2

A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease

NCT06602258
completedphase_1

A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease

NCT04971733
completedphase_1

A Study to Assess Safety, Tolerability, Pharmacokinetics (PK), Immunogenicity, and Pharmacodynamics (PD) of Intravenous Infusions of E2814 in Healthy Participants

NCT04231513

Clinical Trials (5)

Showing 5 of 5 trials
NCT05269394Phase 2

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)

Active Not Recruiting
NCT01760005Phase 2

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

Active Not Recruiting
NCT06602258Phase 2

A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease

Active Not Recruiting
NCT04971733Phase 1

A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease

Completed
NCT04231513Phase 1

A Study to Assess Safety, Tolerability, Pharmacokinetics (PK), Immunogenicity, and Pharmacodynamics (PD) of Intravenous Infusions of E2814 in Healthy Participants

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5